Skip to content

January 2026

Cannabis

What January 2026's 5 new studies found, synthesized from the papers below. All Cannabis research →

The synthesis

Synthesized from 5 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Cannabis, marijuana, THC, cannabidiol, CBD, then ranked by relevance.

The provided studies from January 2026 do not directly report new research findings on cannabis. One study mentions cannabis as a commonly used party drug, and another discusses medical marijuana as a policy lesson, but neither presents original data on cannabis effects. Therefore, no conclusion can be drawn about what research on cannabis found in January 2026.

Confidence in the evidence

Insufficient
  • No study provides original research findings on cannabis from January 2026.
  • One study (article_id 27177) only mentions cannabis as a common party drug without new data.
  • Another study (article_id 31184) references medical marijuana as a policy example, not as a research finding.
  • The remaining studies focus on psychedelics, neuropathic pain, or healthcare provider perspectives, not cannabis research.
How we rate confidence

Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.

Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.

Evidence by study

Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.

Mindset over molecule: comparing self-transcendent and mystical experiences across recreational psilocybin, MDMA, and cannabis use 2026
Unclear

This study compares self-transcendent and mystical experiences across recreational psilocybin, MDMA, and cannabis use, but does not report specific findings for cannabis.

observational

Cannabis-based medicines for chronic neuropathic pain in adults. 2026
Unclear

This is an update of a Cochrane review on cannabis-based medicines for chronic neuropathic pain, but the abstract does not provide results for January 2026.

review

Addressing US Demand for Psychedelic Medicines in the Face of Scientific Uncertainty. 2026
Unclear

This article discusses policy lessons from medical marijuana for psychedelic medicines, but does not present new research on cannabis.

theoretical

Partydrogen im Überblick 2026
Unclear

This overview of party drugs mentions cannabis as commonly consumed, but provides no new research findings on cannabis.

review

Healthcare Providers' Perspectives on Psychedelic-Assisted Therapies Across Clinical Contexts: "I Can Offer Medical Assistance in Dying, but I Can't Prescribe Psychedelics". 2026
Unclear

This study examines healthcare provider perspectives on psychedelic-assisted therapies and does not address cannabis.

qualitative Sample size: 12

Points of agreement

  • No studies provide convergent findings on cannabis research from January 2026.

Conflicts

  • No conflicts identified as no studies present cannabis research findings.

Gaps

  • No original research on cannabis from January 2026 is included in the provided studies.
  • The review on cannabis-based medicines (article_id 19460) does not report results in the abstract.
  • Cannabis is only mentioned peripherally in two studies, not as a primary focus.
Browse these studies in the library